Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a specialist in surgical and medical instruments with annual revenues of $13.55 million, has entered into a significant agreement with WellSpring ...

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 ...

DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...

Orthopedic researchers have developed a promising new nanoparticle hydrogel that can be injected directly into bones weakened by osteoporosis. In a study recently published in the journal Bone ...

This novel approach to hydrogel design should be particularly ... could be successfully used for pharmaceutical high-throughput screening.

UroGen Pharma Ltd. is a biopharmaceutical company ... It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.

Allied Market Research published a report, titled, "Cell Culture Hydrogel Market By Type of Hydrogel (Natural Hydrogels, Synthetic Hydrogels, Hybrid Hydrogels), By Application (Cancer and Stem Cell ...

About UroGen Pharma Ltd. UroGen is a biotech company ... UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the ...